Representative Lisa C. McClain (R-Michigan) recently bought shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.
Representative Lisa C. McClain also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
- Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
- Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
- Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.
AbbVie Price Performance
NYSE ABBV traded up $1.97 during trading hours on Friday, reaching $206.65. The company's stock had a trading volume of 4,430,806 shares, compared to its average volume of 4,938,490. The firm's 50-day moving average price is $191.08 and its 200-day moving average price is $192.20. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $218.66. The company has a market capitalization of $365.06 billion, a price-to-earnings ratio of 98.41, a PEG ratio of 1.33 and a beta of 0.50.
AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). The company had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.65 EPS. On average, equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.
AbbVie Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were issued a $1.64 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.2%. AbbVie's payout ratio is currently 312.38%.
Institutional Trading of AbbVie
Hedge funds have recently made changes to their positions in the stock. Steel Grove Capital Advisors LLC boosted its holdings in shares of AbbVie by 1.7% in the fourth quarter. Steel Grove Capital Advisors LLC now owns 3,110 shares of the company's stock valued at $553,000 after acquiring an additional 52 shares in the last quarter. FF Advisors LLC boosted its holdings in shares of AbbVie by 3.6% in the second quarter. FF Advisors LLC now owns 1,539 shares of the company's stock valued at $286,000 after acquiring an additional 53 shares in the last quarter. Landaas & Co. WI ADV boosted its holdings in shares of AbbVie by 1.1% in the second quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company's stock valued at $920,000 after acquiring an additional 53 shares in the last quarter. Bernardo Wealth Planning LLC boosted its holdings in shares of AbbVie by 2.9% in the second quarter. Bernardo Wealth Planning LLC now owns 1,909 shares of the company's stock valued at $354,000 after acquiring an additional 53 shares in the last quarter. Finally, Private Management Group Inc. boosted its holdings in shares of AbbVie by 1.9% in the first quarter. Private Management Group Inc. now owns 2,938 shares of the company's stock valued at $616,000 after acquiring an additional 54 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.
Insider Activity
In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares of the company's stock, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president owned 58,247 shares of the company's stock, valued at approximately $11,562,611.97. The trade was a 18.58% decrease in their position. The disclosure for this sale can be found here. 0.25% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the company. Guggenheim increased their price target on AbbVie from $216.00 to $227.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Raymond James Financial increased their price target on AbbVie from $227.00 to $236.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. BNP Paribas raised AbbVie to a "hold" rating in a research report on Thursday, May 8th. Daiwa Capital Markets upgraded AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 price objective for the company in a research note on Thursday, August 7th. Finally, Bank of America increased their price target on AbbVie to $204.00 and gave the company a "hold" rating in a research note on Monday, June 9th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and five have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $214.95.
Read Our Latest Stock Analysis on ABBV
About Representative McClain
Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.
McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election.
Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.
AbbVie Company Profile
(
Get Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
See Also
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
MarketBeat All Access